Bernstein lowered the firm’s price target on Agilon Health (AGL) to 88c from $1.40 and keeps a Market Perform rating on the shares. The firm updated its Agilon model forward to reflect Q3 results, lowering its price target due to high prior period medical costs and increased costs for exited markets. The firm added that it remains positive on the sector turnaround and its impacts on Agilon.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Faces NYSE Delisting Notice
- Agilon Health receives noncompliance notification from NYSE
- Agilon Health’s Earnings Call: Mixed Sentiments and Future Prospects
- Agilon Health: Hold Rating Amid Mixed Financial Outlook and Strategic Adjustments
- Agilon Health price target lowered to 50c from $1 at Evercore ISI